logo-loader
viewAmazon.com, Inc.

Amazon said to be exploring the possibility of entering pharmaceuticals

The e-commerce giant has held conversations with Mylan and Sandoz, a unit of Novartis, according to a report

drugs
Some have raised doubts about Amazon entering the pharmacy space

Amazon Inc. (NASDAQ:AMZN) is reportedly in talks with generic drugmakers about entering the pharmaceuticals market.  

The e-commerce giant has held conversations with Mylan (NASDAQ:MYL) and Sandoz, a unit of Novartis, though it is clear whether Amazon plans to enter as a drug wholesaler or retailer, CNBC reported.

Leerink said in a note to investors on Thursday that President of Sandoz US, Peter Goldschmidt, had "met and discussed with Amazon its plans for getting into the U.S. healthcare market" at a recent biopharma event.

A source told CNBC the talks are centred on Amazon taking a role in drug purchasing and general manufacturers are keen to establish a relationship with the company next year.

Such a move could threaten leading distributors, including McKessonAmerisourceBergen and Cardinal Health

However, some in the industry have raised doubts on the possibility of Amazon dipping its toes into the pharmacy space.

Walgreens Boots Alliance CEO Stefano Pessina said he doesn't see it happening because of the regulatory challenges.

"I believe that they will not come in an industry so complicated as our industry," he said during the Forbes Healthcare Summit on Wednesday."I believe in the end they will use their technology in a different way."

Novartis, Mylan and Amazon have declined to comment.

Quick facts: Amazon.com, Inc.

Price: 2442.37 USD

NASDAQ:AMZN
Market: NASDAQ
Market Cap: $1.22 trillion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ioneer Ltd's Bernard Rowe hails new boric acid distribution and sales agreements

ioneer Ltd's (ASX:INR) Bernard Rowe speaks to Proactive's Andrew Scott after securing two distribution and sales agreements for the supply of boric acid from its Rhyolite Ridge Lithium-Boron Project in Nevada, USA. The three-year boric acid distribution and sales agreements were signed with...

2 days, 11 hours ago

2 min read